Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment
Recommended Citation
Eichenfield LF, Stein Gold LF. Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment. Seminars in cutaneous medicine and surgery 2017; 36(2 Suppl 2):S45-S48.
Document Type
Article
Publication Date
3-1-2017
Publication Title
Seminars in cutaneous medicine and surgery
Abstract
Several immunologic mediators-phosphodiesterase (PDE), interleukin (IL), small molecules, and Janus kinase-have been implicated in the pathogenesis of atopic dermatitis, and evidence has shown that blocking these mediators can help modify the disease process. Several new topical medications have been developed that target the enzyme PDE; crisaborole was recently approved by the US Food and Drug Administration (FDA) for the treatment of atopic dermatitis, and phase II studies have been completed on OPA-15406. The phase III clinical trial results of the systemic medication dupilumab, an inhibitor of the IL-4 receptor α subunit (which inhibits both IL-4 and IL-13 signaling), are currently being reviewed by the FDA.
Medical Subject Headings
Antibodies, Monoclonal; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Dermatitis, Atopic; Dermatologic Agents; Humans; Interleukin-4 Receptor alpha Subunit; Phosphodiesterase 4 Inhibitors
PubMed ID
28654711
Volume
36
Issue
2 Suppl 2
First Page
S45
Last Page
S48
